Pfizer Announces Results from XELJANZ XR (tofacitinib) ORAL Shift Study
Pfizer Inc. announced positive results from ORAL Shift, a Phase 3b/4 study in adult patients with moderately to severely active rheumatoid arthritis (RA). Patients who achieved low…
Read More...
Read More...
